- Conditions
- HIV Infection, Acquired Immunodeficiency Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 618
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Apical Periodontitis
- Interventions
- Leukocyte and Platelet Rich Fibrin
- Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Anemia, Leukemia, Neutropenia, Thrombocytopenia
- Interventions
- filgrastim, leridistim, cytarabine, daunorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Infections, Pneumonia, Immune System Diseases, STAT3 Transcription Factor, Job Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Month to 120 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
- Interventions
- AK002, Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Chula Vista, California + 35 more
- Conditions
- Prematurity, Necrotizing Enterocolitis
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2020
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
- Interventions
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more
- Conditions
- Cannabinoid Hyperemesis Syndrome
- Interventions
- Haloperidol
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Bullous Pemphigoid
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Centennial, Colorado + 3 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Montelukast, placebo, 5 mg Montelukast
- Drug · Other
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Enasidenib, Hematopoietic Cell Transplantation
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Buffalo, New York • East Hills, New York
- Conditions
- Neutropenia, Fever
- Interventions
- Karius Test
- Diagnostic Test
- Lead sponsor
- Karius, Inc.
- Industry
- Eligibility
- 1 Year to 22 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
- Interventions
- Dexpramipexole Dihydrochloride, Placebo
- Drug
- Lead sponsor
- Areteia Therapeutics
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 654 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 76
- States / cities
- Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Drug · Biological
- Lead sponsor
- Sawa Ito, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, filgrastim, gp100-fowlpox vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 99 Years
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pneumonia, Community Acquired Pneumonia, Hospital Acquired Pneumonia, Acute Lung Injury
- Interventions
- ticagrelor, placebo
- Drug
- Lead sponsor
- University of Kentucky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Retrospective evaluation of endoscopy prior to study drug, Symptom Survey, Medication Compliance Phone Call, Endoscopy while on study drug, Fluticasone, Omeprazole, Placebo oral capsule
- Diagnostic Test · Other · Drug
- Lead sponsor
- Claire Daniels
- Federal
- Eligibility
- 6 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neutropenia
- Interventions
- Mavorixafor
- Drug
- Lead sponsor
- X4 Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- St. Petersburg, Florida • Iowa City, Iowa • Ann Arbor, Michigan + 4 more
- Conditions
- Eosinophilia, Hypereosinophilic Syndrome, Leukocyte Disorder, Hematologic Diseases
- Interventions
- prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 7 Years to 100 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Covid-19, Coronavirus Disease 2019
- Interventions
- Bempegaldesleukin, Standard of Care, Placebo
- Drug · Other
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Hialeah, Florida • Winter Park, Florida • Mesquite, Texas
- Conditions
- Chemotherapy-induced Neutropenia, Breast Cancer
- Interventions
- LA-EP2006, Neulasta®
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 10
- States / cities
- Hot Springs, Arkansas • Jonesboro, Arkansas • Corona, California + 7 more
- Conditions
- Neutropenia, Infection
- Interventions
- Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine
- Drug · Biological · Device
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- Not listed
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 13
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- aldesleukin, filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, etoposide, pegylated liposomal doxorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland